Effects of 6-keto-prostaglandin E1 on ascitic hepatoma-130 in vivo comparison with chemotherapeutic agents.
The inhibitory effect of 6-keto-prostaglandin E1 (pGE1) on the growth and survival of ascitic hepatoma (AH-130) cells in vivo was compared with currently used chemotherapeutic agents. Three days after receiving an intraperitoneal injection of 3 X 10(6) AH-130 tumor cells, Donrhyu rats were injected intravenously or intraperitoneally with one of the following: Thromboxane B2 (TXB2) (0.5 mg/kg), 6-keto-pGE1 (0.5 mg/kg), Mitomycin C (MMC) (1.5 mg/kg), or MMC + 6-keto-pGE1 (1.5 mg/kg + 0.5 mg/kg). The mean survival time, median survival time, and increase of life survival percent (ILS%) during a 60 day period revealed that both 6-keto-pGE1 and 6-keto-pGE1 + MMC significantly inhibited AH-130 tumor cell growth, while TXB2 promoted tumor cell growth. We conclude that 6-keto-pGE1 like anti-tumor agents such as MMC, Diketocoriolin B, Carbazilquinon, Endoxan, and 5-Fluorouracil, can significantly inhibit growth of AH-130 tumor cells in vivo, particularly when administered in combination with the anti-tumor agent MMC.
D000527:Alprostadil / Q000031:analogs & derivatives*; D000818:Animals; D000970:Antineoplastic Agents; D005260:Female; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000648:ultrastructure; D008854:Microscopy, Electron; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D011458:Prostaglandins E / Q000627:therapeutic use*; D051381:Rats; D013929:Thromboxane B2 / Q000627:therapeutic use; D013997:Time Factors
D000970:Antineoplastic Agents; D008937:Mitomycins; D011458:Prostaglandins E; D016685:Mitomycin; D013929:Thromboxane B2; C022950:6-ketoprostaglandin E1; D000527:Alprostadil